nach oben

Tumor Biology

Erschienen in:

01.02.2014 | Research Article

Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation

verfasst von: Gang He, Yan Wang, Xueli Pang, Bo Zhang

Erschienen in: Tumor Biology | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Abstract

Radiotherapy is one of the main treatments for clinical cancer therapy. However, its application was limited due to lack of radiosensitivity in some cancers. Trichostatin A (TSA) is a classic histone deacetylases inhibitor (HDACi) that specifically inhibits the biochemical functions of HDAC and is demonstrated to be an active anticancer drug. However, whether it could sensitize colon cancer to radiation is not clear. Our results showed that TSA enhanced the radiosensitivity of colon cancer cells as determined by CCK-8 and clonogenic survival assay. Moreover, apoptotic cell death induced by radiation was enhanced by TSA treatment. Additionally, TSA also induced autophagic response in colon cancer cells, while autophagy inhibition led to cell apoptosis and enhanced the radiosensitivity of colon cancer cells. Our data suggested that inhibition of cytoprotective autophagy sensitizes cancer cell to radiation, which might be further investigated for clinical cancer radiotherapy.

Nur mit Berechtigung zugänglich

Liu S et al. Randomized, controlled phase II study of post-surgery radiotherapy combined with recombinant adenoviral human p53 gene therapy in treatment of oral cancer. Canc Gene Ther. 2013;20(6):375–8.CrossRef

Lövey J et al. Radiosensitivity of human prostate cancer cells can be modulated by inhibition of 12-lipoxygenase. Cancer Lett. 2013;335(2):495–501.PubMedCrossRef

Benzina S et al. High-LET radiation combined with oxaliplatin induce autophagy in U-87 glioblastoma cells. Cancer Lett. 2008;264(1):63–70.PubMedCrossRef

Weichert W et al. Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo. Clin Cancer Res. 2008;14(6):1669–77.PubMedCrossRef

Weichert W et al. Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. Lancet Oncol. 2008;9(2):139–48.PubMedCrossRef

Weichert W. HDAC expression and clinical prognosis in human malignancies. Cancer Lett. 2009;280(2):168–76.PubMedCrossRef

Johnstone RW. Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat Rev Drug Discov. 2002;1(4):287–99.PubMedCrossRef

Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov. 2006;5(9):769–84.PubMedCrossRef

Carafa V, Nebbioso A, Altucci L. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Pat Anticancer Drug Discov. 2011;6(1):131–45.PubMedCrossRef

10.

Mottet D, Castronovo V. Histone deacetylases: anti-angiogenic targets in cancer therapy. Curr Cancer Drug Targets. 2010;10(8):898–913.PubMedCrossRef

11.

Bots M, Johnstone RW. Rational combinations using HDAC inhibitors. Clin Cancer Res. 2009;15(12):3970–7.PubMedCrossRef

12.

Gore SD et al. Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res. 2006;66(12):6361–9.PubMedCrossRef

13.

Caron C, Boyault C, Khochbin S. Regulatory cross-talk between lysine acetylation and ubiquitination: role in the control of protein stability. Bioessays. 2005;27(4):408–15.PubMedCrossRef

14.

Fantin VR et al. Constitutive activation of signal transducers and activators of transcription predicts vorinostat resistance in cutaneous T-cell lymphoma. Cancer Res. 2008;68(10):3785–94.PubMedCrossRef

15.

Oh M, Choi IK, Kwon HJ. Inhibition of histone deacetylase1 induces autophagy. Biochem Biophys Res Commun. 2008;369(4):1179–83.PubMedCrossRef

16.

Gammoh N et al. Role of autophagy in histone deacetylase inhibitor-induced apoptotic and nonapoptotic cell death. Proc Natl Acad Sci U S A. 2012;109(17):6561–5.PubMedCentralPubMedCrossRef

17.

Cao Y, Klionsky DJ. Physiological functions of Atg6/Beclin 1: a unique autophagy-related protein. Cell Res. 2007;17(10):839–49.PubMedCrossRef

18.

Sharma S, Kelly TK, Jones PA. Epigenetics in cancer. Carcinogenesis. 2010;31(1):27–36.PubMedCrossRef

19.

Berdasco M, Esteller M. Aberrant epigenetic landscape in cancer: how cellular identity goes awry. Dev Cell. 2010;19(5):698–711.PubMedCrossRef

20.

Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286–98.PubMedCrossRef

21.

Liu Y, He G, Wang Y, Guan X, Pang X, Zhang B. MCM-2 is a therapeutic target of Trichostatin A in colon cancer cells. Toxicol Lett. 2013;221(1):23–30.PubMedCrossRef

22.

Rhodes LV et al. The histone deacetylase inhibitor trichostatin A alters microRNA expression profiles in apoptosis-resistant breast cancer cells. Oncol Rep. 2012;27(1):10–6.PubMed

23.

Frew AJ et al. Combination therapy of established cancer using a histone deacetylase inhibitor and a TRAIL receptor agonist. Proc Natl Acad Sci U S A. 2008;105(32):11317–22.PubMedCentralPubMedCrossRef

24.

Camphausen K, Tofilon PJ. Inhibition of histone deacetylation: a strategy for tumor radiosensitization. J Clin Oncol. 2007;26:4051–6.CrossRef

25.

Folkvord S et al. Radiosensitization by SAHA in experimental colorectal carcinoma models—in vivo effects and relevance of histone acetylation status. Int J Radiat Oncol Biol Phys. 2009;74(2):546–52.PubMedCrossRef

26.

Ree AH et al. Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic radiation and Vorinostat (PRAVO) phase 1 study. Lancet Oncol. 2010;11(5):459–64.PubMedCrossRef

27.

Chowdhury S et al. Histone deacetylase inhibitor belinostat represses survivin expression through reactivation of transforming growth factor beta (TGFbeta) receptor II leading to cancer cell death. J Biol Chem. 2011;286(35):30937–48.PubMedCrossRef

28.

Kondo Y et al. The role of autophagy in cancer development and response to therapy. Nat Rev Cancer. 2005;5(9):726–34.PubMedCrossRef

29.

Livesey KM et al. Autophagy inhibition in combination cancer treatment. Curr Opin Investig Drugs. 2009;10(12):1269–79.PubMed

30.

Sy LK et al. Timosaponin A-III induces autophagy preceding mitochondria-mediated apoptosis in HeLa cancer cells. Cancer Res. 2008;68(24):10229–37.PubMedCrossRef

31.

Akar U et al. Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy. 2008;4(5):669–79.PubMed

32.

Funderburk SF, Wang QJ, Yue Z. The Beclin 1–VPS34 complex—at the crossroads of autophagy and beyond. Trends Cell Biol. 2010;20(6):355–62.PubMedCentralPubMedCrossRef

33.

Dai ZJ et al. Antitumor effects of rapamycin in pancreatic cancer cells by inducing apoptosis and autophagy. Int J Mol Sci. 2013;14(1):273–85.PubMedCentralCrossRef

Titel: Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation
verfasst von: Gang He
Yan Wang
Xueli Pang
Bo Zhang
Publikationsdatum: 01.02.2014
Verlag: Springer Netherlands
Erschienen in: Tumor Biology / Ausgabe 2/2014
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI: https://doi.org/10.1007/s13277-013-1134-z

Neu im Fachgebiet Onkologie

20.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Inhibition of autophagy induced by TSA sensitizes colon cancer cell to radiation

Abstract

Neu im Fachgebiet Onkologie

Blasenkarzinom – Biomarker statt Zytologie?

Prostatakarzinom: EU initiiert neues Screeningkonzept

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Analysis of the association of interleukin-17 gene polymorphisms with gastric cancer risk and interaction with Helicobacter pylori infection in a Chinese population

Murine double minute 2 rs2279744 polymorphism and hepatocellular carcinoma risk in East Asians: a meta-analysis

A critical review on HE4 performance in endometrial cancer: where are we now?

COL1A1 polymorphism is associated with risks of osteosarcoma susceptibility and death

Inhibitory effect and mechanism of mesenchymal stem cells on liver cancer cells

Alternol inhibits migration and invasion of human hepatocellular carcinoma cells by targeting epithelial-to-mesenchymal transition

Neu im Fachgebiet Onkologie

Blasenkarzinom – Biomarker statt Zytologie?

Prostatakarzinom: EU initiiert neues Screeningkonzept

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie